GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Journal of Clinical Pathology, BMJ, Vol. 73, No. 10 ( 2020-10), p. 648-655
    Abstract: The identification of actionable DNA mutations associated with a patient’s tumour is critical for devising a targeted, personalised cancer treatment strategy. However, these molecular analyses are typically performed using tissue obtained via biopsy, which involves substantial risk and is often not feasible. In addition, biopsied tissue does not always reflect tumour heterogeneity, and sequential biopsies to track disease progression (eg, emergence of drug resistance mutations) are not well tolerated. To overcome these and other biopsy-associated limitations, we have developed non-invasive ‘liquid biopsy’ technologies to enable the molecular characterisation of a patient’s cancer using peripheral blood samples. Methods The Target Selector ctDNA platform uses a real-time PCR-based approach, coupled with DNA sequencing, to identify cancer-associated genetic mutations within circulating tumour DNA. This is accomplished via a patented blocking approach suppressing wild-type DNA amplification, while allowing specific amplification of mutant alleles. Results To promote the clinical uptake of liquid biopsy technologies, it is first critical to demonstrate concordance between results obtained via liquid and traditional biopsy procedures. Here, we focused on three genes frequently mutated in cancer: EGFR (Del19, L858, and T790), BRAF (V600) and KRAS (G12/G13). For each Target Selector assay, we demonstrated extremely high accuracy, sensitivity and specificity compared with results obtained from tissue biopsies. Overall, we found between 93% and 96% concordance to blinded tissue samples across 127 clinical assays. Conclusions The switch-blocker technology reported here offers a highly effective method for non-invasively determining the molecular signatures of patients with cancer.
    Type of Medium: Online Resource
    ISSN: 0021-9746 , 1472-4146
    RVK:
    Language: English
    Publisher: BMJ
    Publication Date: 2020
    detail.hit.zdb_id: 2028928-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2013
    In:  Cancer Research Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4223-4223
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4223-4223
    Abstract: We previously described the utility of the CEE-Selector assay for the sensitive detection of the EGFR T790M mutation in plasma samples from lung cancer patients. The assay combined the CEE-Selector assay with melt curve analysis of the mutant PCR product, followed by Sanger sequencing to verify the presence of the mutation. We showed that the assay selectively amplified the mutant sequence compared to wild type by & gt;100,000 fold. We have now expanded the CEE-Selector assay to include additional mutations relevant to patient care (KRAS, BRAF V600E, EGFR L858R). We are presenting data of allele/mutation-specific as well as “footprint” versions of the CEE-Selector assay. The “footprint” version of the assay provides for the interrogation of “hot spot” regions of the genome where multiple cancer relevant mutations are located within a small region, as in the case of KRAS codons 12 and 13 where the CEE-Selector assay is sensitive to all known mutations. Combining the “footprint” version of the CEE-Selector assay with next-generation sequencing, allows us to simultaneously detect, with extremely high sensitivity, a broad array of mutations of interest. Additionally, when used with barcoding, samples from multiple patients can be interrogated simultaneously. The combination of the CEE-Selector assay with next-generation sequencing increases the sensitivity of sequencing by a factor of & gt;1000 and allows for simultaneous sensitive detection of multiple mutations from complex samples, like plasma, where the mutations may be very rare. With the increases in sensitivity made possible using the CEE-Selector assay, the limiting factor for the sensitive detection of mutations/alleles is determined fundamentally by the ability to obtain at least a single copy of the mutant allele within the sample under interrogation. Citation Format: Vassilios Alexiadis, Tim Watanaskul, Lyle Arnold. Combining the CEE-selector assay with sequencing for sensitive mutation detection in cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4223. doi:10.1158/1538-7445.AM2013-4223
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2012
    In:  Cancer Research Vol. 72, No. 8_Supplement ( 2012-04-15), p. 3198-3198
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 3198-3198
    Abstract: Molecular assays for the identification of rare allele occurrences are important tools for proper cancer classification and treatment. A prime example is the T790M mutation in EGFR which leads to resistance to the tyrosine kinase inhibitors gefitinib (Iressa®) and erlotinib (Tarceva®) used in the treatment of non-small cell lung cancer (NSCLC). Identification of the T790 mutation in cancer-shed particles in blood (either as whole cells or subcellular vesicles) calls out the need for an alternative cancer treatment. We have developed a highly sensitive PCR-based assay which allows the identification of the T790M mutation in blood plasma (either when present in mRNA or genomic DNA). The assay combines Real-Time PCR as well as melt curve analysis of the mutant PCR product and is followed by sequencing to verify the presence of the mutation. The Selector Assay is based on a wild-type specific PCR blocker and allows the mutant template to be amplified in a high background of wild-type template. A few copies of T790M mutant can be detected in greater than a 1000-fold excess of wild-type. Data using the Selector Assay with clinical lung cancer samples showing the identification of T790M in genomic DNA as well as mRNA in blood plasma and in CTCs will be presented. The Selector Assay can be applied to other mutations relevant to cancer and is a valuable tool for clinical diagnostics. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3198. doi:1538-7445.AM2012-3198
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 33, No. 15_suppl ( 2015-05-20), p. e19086-e19086
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2015
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Journal of Biological Chemistry, Elsevier BV, Vol. 276, No. 23 ( 2001-01), p. 20397-20406
    Type of Medium: Online Resource
    ISSN: 0021-9258
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2001
    detail.hit.zdb_id: 2141744-1
    detail.hit.zdb_id: 1474604-9
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...